Corbus Pharmaceuticals Holdings, Inc. (CRBP) is “One to Watch”
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, recently reported its third quarter financial results (http://nnw.fm/ewaP8) for the three months ended September 30, 2016. CRBP reported a net loss for the third quarter due to increased spending on clinical studies for systemic sclerosis and CF, plus increased staffing costs, bonuses, and other expenditures. However, the company ended the third quarter with just under $19 million in cash and cash equivalents, which it believes to be sufficient to meet its operating and capital requirements through the end of…